ArticleDiabetology & metabolic syndrome2023
Predictive value of estimated pulse wave velocity for cardiovascular and all-cause mortality in individuals with obesity.
Article in Diabetology & metabolic syndrome, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of estimated pulse wave velocity with cardiovascular disease outcomes and all-cause death-a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2025Pooled it
- Article
- Association of estimated pulse wave velocity and metabolic markers with cognitive impairment risk in diabetes : Exploring cognitive impairment risks in diabetic patients.BMC endocrine disorders · 2026Article
- Association of estimated pulse wave velocity with risk of in-hospital mortality in patients with sepsis: a study based on Medical Information Mart for Intensive Care database.BMC infectious diseases · 2026Article
- Advances in the Role of Adipose Tissue in Promoting Injury Repair and Resist Infection.Immunity, inflammation and disease · 2026Review
- Article
- Observational
- Association of estimated pulse wave velocity with all-cause mortality and cardiovascular mortality in obstructive sleep apnea patients: results from NHANES.Frontiers in cardiovascular medicine · 2025Article
- Estimated pulse wave velocity as a forefront indicator of developing metabolic syndrome in Korean adults.The Korean journal of internal medicine · 2024Article
- The Role of Carotid-Femoral Pulse Wave Velocity in a Metabolic Syndrome Patient with Sudden Cardiac Arrest: A Case Report.Healthcare (Basel, Switzerland) · 2024Article
- Estimated Pulse Wave Velocity as a Novel Non-Invasive Biomarker for Metabolic Syndrome Among People Living with HIV.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- System inflammation response index: a novel inflammatory indicator to predict all-cause and cardiovascular disease mortality in the obese population.Diabetology & metabolic syndrome · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundEstimated pulse wave velocity (ePWV) has revealed excellent performance in predicting cardiovascular disease (CVD) risk. However, whether ePWV predicts all-cause mortality and CVD mortality in populations with obesity remains elusive.
methodsWe performed a prospective cohort including 49,116 participants from the National Health and Nutrition Examination Survey from 2005 to 2014. Arterial stiffness was evaluated by ePWV. Weighted univariate, multivariate Cox regression and receiver operating characteristic curve (ROC) analysis was used to assess the effects of ePWV on the risk of all-cause and CVD mortality. In addition, the two-piecewise linear regression analysis was used to describe the trend of ePWV affecting mortality and identify the thresholds that significantly affect mortality.
resultsA total of 9929 participants with obesity with ePWV data and 833 deaths were enrolled. Based on the multivariate Cox regression results, the high ePWV group had a 1.25-fold higher risk of all-cause mortality and a 5.76-fold higher risk of CVD mortality than the low-ePWV group. All-cause and CVD mortality risk increased by 123% and 44%, respectively, for every 1 m/s increase in ePWV. ROC results showed that ePWV had an excellent accuracy in predicting all-cause mortality (AUC = 0.801) and CVD mortality (AUC = 0.806). Furthermore, the two-piecewise linear regression analysis exhibited that the minimal threshold at which ePWV affected participant mortality was 6.7 m/s for all-cause mortality and 7.2 m/s for CVD mortality.
conclusionsePWV was an independent risk factor for mortality in populations with obesity. High ePWV levels were associated with an increased all-cause and CVD mortality. Thus, ePWV can be considered a novel biomarker to assess mortality risk in patients with obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.